Cancer cells utilize normal metabolic processes out of context to promote tumor survival. For example, Otto Warburg and others discovered that tumors have increased glucose uptake, glycolysis, and lactate production, often with a reduction in citric acid cycle. While ?aerobic glycolysis? at first glance is energetically expensive for tumor cells because it circumvents high ATP production from the citric acid cycle, it allows cancer cells to survive under low nutrient or low oxygen conditions and to instead use glycolytic intermediates for the synthesis of essential cellular building blocks without further energy investment. This change in metabolite regulation suggests a powerful method for monitoring and diagnosing cancer. This project seeks to develop surface enhanced Raman scattering (SERS) as online detection method for the characterization of metabolites from breast cancer tumor models. Using the SERS results from tumor lysates, diagnostic algorithms will be constructed to improve treatment for cancer. Results show that fluid dynamics can be used to increase the reproducibility and sensitivity of SERS detection in flowing liquids. We propose to develop methodology to enable the use this innovation to investigate metabolites in cancer cell lysates using capillary electrophoresis coupled to a SERS flow detector. We will investigate known metabolites that have been linked to cancer, as well as examine key metabolites associated with oncogenes. The SERS data collected will be used to formulate diagnostic algorithms that can provide a yes/no indicator of cancer.
The specific aims of this project are as follows:
AIM 1. Demonstrate the utility of the novel flow detector to assess changes in key metabolites from tumor cell lysates. The tumor cell lysates will be compared with non-cancerous cell lysates to identify trends in these metabolites relevant to breast cancer.
AIM 2. Compare the identification and quantification capabilities with the current gold standard, LC- MS.
This aim will assess how SERS characterization both compares with existing technology but also increases coverage of the metabolome.
AIM 3. We will use the metabolites to develop statistical machine learning algorithms to predict the sample label (cancer or not). The predictor obtained will be used as a diagnostic tool of cancer. The development of new technologies that provide unique chemical specific information will enable improved diagnostic assays for the treatment of cancer.

Public Health Relevance

to Public Health. The proposed research seeks to develop new technology for the diagnosis and treatment of cancer. Cancer exhibits misregulation of metabolic process relative to normal cells. The technology developed here will provide new methods to monitor changes in metabolism and develop diagnostics to improve treatment.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Exploratory/Developmental Grants Phase II (R33)
Project #
5R33CA206922-04
Application #
9532126
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Sorg, Brian S
Project Start
2016-08-01
Project End
2019-07-31
Budget Start
2018-08-01
Budget End
2019-07-31
Support Year
4
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Ohio State University
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Nguyen, Anh H; Deutsch, Jessica M; Xiao, Lifu et al. (2018) Online Liquid Chromatography-Sheath-Flow Surface Enhanced Raman Detection of Phosphorylated Carbohydrates. Anal Chem 90:11062-11069
Dai, Chen; Arceo, Jennifer; Arnold, James et al. (2018) Metabolomics of oncogene-specific metabolic reprogramming during breast cancer. Cancer Metab 6:5
Sawe, Rispah T; Mining, Simeon K; Ofulla, Ayub V et al. (2017) Tumor infiltrating leukocyte density is independent of tumor grade and molecular subtype in aggressive breast cancer of Western Kenya. Trop Med Health 45:19
Nguyen, Anh H; Peters, Emily A; Schultz, Zachary D (2017) Bioanalytical applications of surface-enhanced Raman spectroscopy: de novo molecular identification. Rev Anal Chem 36: